Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The …
MS Fernández, MA Sánchez, F Arribas… - Cardiology …, 2022 - journals.viamedica.pl
Background: The aim of the study was to evaluate the performance of the 2MACE in patients
with atrial fibrillation (AF) treated with rivaroxaban and to improve the accuracy of 2MACE …
with atrial fibrillation (AF) treated with rivaroxaban and to improve the accuracy of 2MACE …
[HTML][HTML] Adverse clinical outcomes and associated predictors in rivaroxaban-treated atrial fibrillation patients with renal impairment
JM Rivera-Caravaca, MA Sanchez… - The American Journal of …, 2023 - Elsevier
Renal impairment confers worse prognosis in patients with atrial fibrillation (AF) but there is
scarce evidence about the influence of direct-acting oral anticoagulants in routine clinical …
scarce evidence about the influence of direct-acting oral anticoagulants in routine clinical …
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
AJ Camm, P Amarenco, S Haas, S Hess… - European heart …, 2016 - academic.oup.com
Aims Although non-vitamin K antagonist oral anticoagulants are recommended for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF) based on clinical trial …
prevention in patients with non-valvular atrial fibrillation (NVAF) based on clinical trial …
Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries
F Marin, MS Fernández, I Lekuona… - Journal of …, 2022 - becarispublishing.com
Objective: To analyze the effectiveness and safety of rivaroxaban in patients with atrial
fibrillation (AF). Methods: The clinical profile and outcomes of the EMIR study were indirectly …
fibrillation (AF). Methods: The clinical profile and outcomes of the EMIR study were indirectly …
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective …
MA Esteve-Pastor, JM Rivera-Caravaca… - European Heart …, 2023 - academic.oup.com
Background Assessing bleeding risk during the decision-making process of starting oral
anticoagulation (OAC) therapy in atrial fibrillation (AF) patients is essential. Several bleeding …
anticoagulation (OAC) therapy in atrial fibrillation (AF) patients is essential. Several bleeding …
Comparison of warfarin, rivaroxaban, and dabigatran for effectiveness and safety in atrial fibrillation patients with different CHA2DS2-VASc scores: a retrospective …
Y Zhao, H Ren, S Xu - BMC Cardiovascular Disorders, 2024 - Springer
Background This retrospective cohort study aims to compare the effectiveness and safety of
warfarin, rivaroxaban, and dabigatran in atrial fibrillation (AF) patients with different …
warfarin, rivaroxaban, and dabigatran in atrial fibrillation (AF) patients with different …
Comparisons of rivaroxaban following different dosage criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian patients with atrial fibrillation
Background The ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial …
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial …
A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
PH Liu, ZH Liu, MH Niu, P Chen, YB Shi… - Frontiers in …, 2022 - frontiersin.org
Objective To compare the clinical benefits of rivaroxaban and warfarin in patients with non-
valvular atrial fibrillation (NVAF) with high bleeding risk. Methods A retrospective study was …
valvular atrial fibrillation (NVAF) with high bleeding risk. Methods A retrospective study was …
Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?
YP Quezada, JL Bonilla Palomas… - Future …, 2018 - Taylor & Francis
Aim: To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation
treated with rivaroxaban. Methods: Retrospective study in which patients treated with …
treated with rivaroxaban. Methods: Retrospective study in which patients treated with …
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1
CI Coleman, AGG Turpie, TJ Bunz… - European Heart …, 2019 - academic.oup.com
Aims To compare the effectiveness and safety of standard-dose rivaroxaban (20 mg od) and
warfarin in non-valvular atrial fibrillation (NVAF) patients with a non-sex-related CHA2DS2 …
warfarin in non-valvular atrial fibrillation (NVAF) patients with a non-sex-related CHA2DS2 …
相关搜索
- atrial fibrillation outcomes in patients
- atrial fibrillation predictive value
- atrial fibrillation risk scores
- safety of rivaroxaban fibrillation patients
- atrial fibrillation rivaroxaban dosing
- atrial fibrillation emir registry
- clinical practice outcomes in patients
- atrial fibrillation clinical practice
- cha2ds2 vasc fibrillation patients
- associated predictors fibrillation patients
- atrial fibrillation stroke prevention
- atrial fibrillation low dose
- emir registry risk scores
- renal impairment fibrillation patients
- indirect comparison outcomes in patients
- atrial fibrillation dosage criteria